← Leaderboards

Long Island University

Greenvale, NY

$14,353,090

Total funding

48

Grants

Funding over time

peak $3.1M · FY2007–25

$5M$3.8M$2.5M$1.3M$0

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NSF$10,705,288 · 38

USDA$2,738,379 · 8

DOD$560,625 · 1

CDC$348,798 · 1

By mechanism

—$14,004,292 · 47

H75$348,798 · 1

Investigators at Long Island University

Investigator-initiated All funding

Investigatorsi

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

Not enough data

Largest grants

Long Island Mathematics and Teacher Education Scholarship Program$1,450,000

· FY2018 · EDU

EF: Collaborative Research: MTM 2: Marine Invertebrate Microbiome Assembly, Diversification, and Coevolution$1,202,860

· FY2021 · BIO

Scholarship and Excellence in Secondary Science Education (SESSE)$1,174,669

· FY2011 · EDU

CAREER: Investigating Host Response in the Pathogenesis of FV3 (Ranavirus sp) in Wood Frogs, Rana sylvatica (Lithobates sylvaticus)$1,145,610

· FY2021 · BIO

Cultivating Academic Success in Computing$749,765

· FY2023 · EDU

** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** METRITIS IS ONE OF THE MOST COMMON DISEASES IN DAIRY COWS CAUSED BY INFECTION OF THE UTERUS WITH MULTIPLE BACTERIA AFTER GIVING BIRTH. AN AVERAGE INCIDENCE OF BOVINE METRITIS IS ABOUT 20% IN A HERD, AND IT CAN REACH UP TO 47%. TO TREAT METRITIS, ANTIBIOTICS HAVE LONG BEEN USED IN US DAIRY FARMS, DESPITE GROWING CONCERNS ABOUT ANTIBIOTIC RESISTANCE AND THE FACT THAT THE SUCCESS RATE FOR ANTIBIOTIC THERAPY IS LESS THAN 75%. THEREFORE, DEVELOPMENT OF EFFECTIVE ALTERNATIVE THERAPIES FOR BOVINE METRITIS IS URGENTLY NEEDED. OUR LONG-TERM GOAL IS TO DEVELOP A SAFE AND EFFECTIVE ALTERNATIVE TO ANTIBIOTICS FOR THE TREATMENT OF BOVINE METRITIS. OUR HYPOTHESIS IS THAT CHITOSAN MICROPARTICLES ENGINEERED IN THIS WORK WILL EFFECTIVELY TARGET THE INFECTED UTERUS, LEADING TO RESOLUTION OF METRITIS. TO ATTAIN OUR GOAL, OUR SPECIFIC AIMS ARE TO (1) DEVELOP CHITOSAN MICROPARTICLES THAT SPECIFICALLY ELIMINATE UTERINE PATHOGENS AND REGULATE INFLAMMATION, AND (2) DETERMINE EFFECTIVENESS OF CHITOSAN MICROPARTICLES FOR TREATMENT OF METRITIS IN THE LABORATORY AS WELL AS FIELD APPLICATION. UPON COMPLETION OF THESE AIMS, WE EXPECT OUR CONTRIBUTION TO BE THE DEVELOPMENT OF EFFECTIVE ALTERNATIVES FOR TREATMENT OF BOVINE METRITIS AND A PATENT APPLICATION. THESE RESULTS ARE EXPECTED TO HAVE POSITIVE IMPACTS ON ANIMALS BY IMPROVING THEIR HEALTH AND WELFARE, ON STAKEHOLDERS BY INCREASING CURE RATE AND FARM PROFITABILITY, AND ON THE PUBLIC BY REDUCING USE OF ANTIBIOTICS AND IMPROVING FOOD SAFETY.$650,000

· FY2023 · National Institute of Food and Agriculture

** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** BOVINE RESPIRATORY DISEASE (BRD) IS THE MOST COSTLY DISEASE AFFECTING NORTH AMERICAN BEEF CATTLE, AND IS RESPONSIBLE FOR 40-50% OF THE MORTALITY AND 70-80% OF THE MORBIDITY IN THESE ANIMALS, RESULTING IN OVER $3 BILLION/YEAR IN LOSSES TO THE CATTLE INDUSTRY. DECREASED WEIGHT GAIN AND PERFORMANCE AFFECTS AN ADDITIONAL 10% OF THESE ANIMALS. BRD IN PRE-WEANED CALVES ALONE COSTS THE US BEEF COW-CALF INDUSTRY ~$165 MILLION ANNUALLY. BRD IS THE LEADING CAUSE OF MORBIDITY AND MORTALITY IN U.S. FEEDLOT AND STOCKER CATTLE AND THE SECOND LEADING CAUSE OF LOSS IN DAIRY CALVES. THE PRIMARY BACTERIAL AGENTS RESPONSIBLE FOR BRD ARE H. SOMNI, MANNHEIMIA HAEMOLYTICA, PASTEURELLA MULTOCIDA, AND MYCOPLASMA BOVIS. HOWEVER, H. SOMNI CAN ALSO CAUSE A WIDE RANGE OF INFECTIONS OTHER THAN BRD, AND IS THEREFORE THE TARGET BACTERIUM FOR THIS INVESTIGATION. CURRENT COMMERICAL VACCINES CONSISTING OF KILLED BACTERIA THAT HAVE BEEN GROWN IN VITRO ARE NOT ADEQUATELY EFFECTIVE AT PREVENTING BRD AND SOME OTHER SYSTEMIC INFECTIONS. WE AND OTHERS HAVE SHOWN THAT OPPORTUNISTIC BACTERIA EXPRESS NOVEL PROTEINS IN THEHOST IN ORDER TO SEQUESTER IRON THAT IS BOUND TO HOST PROTEINS, SUCH AS TRANSFERRIN AND HEMIN. THESE PROTEINS ARE NOT PRODUCED IN VITRO WHERE ADEQUTE IRON IS AVAILABLE. FURTHERMORE, DURING CHRONIC INFECTIONS BACTERIA PERSIST IN THE HOST IN THEFORM OF A BIOFILM. WE HAVE SHOWN THAT HALF OF THE BACTERIAL GENOME IS DIFFERENTIALLY EXPRESSED WHEN THE BACTERIA ARE IN A BIOFILM, COMPARED TO WHEN GROWN SHAKING OR IN A FERMENTOR, AND THAT MANY NOVEL PROTEINS ARE PRESENT WHEN THE BACTERIA ARE IN A BIOFILM. IN ADDITIION, H. SOMNIAND OTHER BACTERIA MAY BE ABLE TO PRESIST IN PHAGOCYTIC OR OTHER CELLS AND AVOID RECOGNITION BY ANTIBODIES. THEREFORE, MANY POTENTIALLY PROTECTIVE ANTIBODIES ARE NOT PRODUCEDOR ABLE TO REACH THE BACTERIA, AND AN IMPORTANT CELLULAR IMMUNE RESPONSE IS LACKING.H. SOMNIAND OTHER GRAM-NEGATIVE PATHOGENS ALSO PRODUCE ENDOTOXIN, WHICH RESULTS IN SERIOUS SIDE-EFFECTS IN SOME IMMUNIZED ANIMALS. AS A RESULT OF THE DEFICIENCIES IN CURRENT VACCINES, WE WILL PRODUCE A VACCINE THAT INCLUDES THE COMPONENTS OF THE BACTERIA THAT ARE EXPRESSED IN THE HOST (IRON BINDING PROTEINS AND BIOFILM MATRIX COMPONENTS) IN THE FORM OF OUTER MEMBRANE VESSICLES (OMV), WHICH ARE RELATIVELY SIMPLE TO PREPARE, COMBINED WITHTHE BIOFILM MATRIX ANDA NOVEL VACCINE THAT HAS BEEN SHOWN TO GREATLY STIMULATE BOTH THE HUMORAL AND CELLULAR IMMUNE RESPONSES OF THE HOST TO DESIRED ANTIGENIC COMPONENTS. TO PRODUCE A SAFE VACCINE WE WILL GENERATE A MUTANT THAT LACKS ONLY ENDOTOXIC ACTIVITY THROUGH THE MUTATION OF ONE GENE BY AN ESTABLISHED ALLELIC EXCHANGE METHOD. OMV FROM THE MUTANT BACTERIA WILL BE GROWN TO PRODUCE IRON-BINDING PROTEINS AND OTHER OURTER MEMBRANE PROTEINS, WHICH ARE COMBINED WITH BIOFILM MATRIX AND THE ADJUVANT. THOROUGH GENETIC AND BIOCHEMICAL CHARACTERIZATION OF THE MUTANT WILL BE CARRIED OUT. THE OPTIMAL CONCENTRATIONOF ALL COMPONENTS WILL FIRST BE DETERMINED IN HOLSTEIN CALVES FOR IMMU,NE EFFICACY AND SAFETY, AND COMPARED TO COMMERCIAL BACTERINS. ONCE OPTIMIZED, ADDITIONAL SAFETY DATA WILL BE COLLECTED ON A LARGE NUMBER OF COMMERCIAL BEEF CALVES IN COMPARISON TO COMMERCIAL VACCINES. APPROVED STATISTICAL ANALYSES WILL BE USED FOR ALL DATA ANALYSIS.$627,000

· FY2023 · National Institute of Food and Agriculture

PTEROSTILBENE, A POTENT ANALOG OF RESVERATROL, A THERAPEUTIC AGENT IN PROSTATE CANCER: EPIGENETIC MECHANISMS OF ACTION$560,625

· FY2013 · Department of the Army

**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** METRITIS IS AN INFLAMMATORY UTERINE DISEASE CAUSED BY ANAEROBIC BACTERIA AND AFFECTS &GE;20% OF POSTPARTUM DAIRY COWS. THIS DISEASE DECREASES MILK YIELD AND FERTILITY AND INCREASES MANAGEMENT COSTS FOR DAIRY HERDS. OVER-GROWTH OF 3 SPECIFIC ANAEROBIC BACTERIA (FUSOBACTERIUM NECROPHORUM, BACTEROIDES PYOGENES, AND PORPHYROMONAS LEVII), WHICH ARE NORMALLY FOUND IN THE UTERUS OF HEALTHY DAIRY COWS, HAS BEEN SHOWN TO BE RESPONSIBLE FOR CAUSING METRITIS. HOWEVER, IT IS UNCLEAR WHY THEY INCREASE IN THE UTERUS AND BECOME HARMFUL. OUR HYPOTHESIS IS THAT THESE 3 BACTERIAL SPECIES PRODUCE METABOLITES, WHICH MAKE IT POSSIBLE FOR THE BACTERIA TO MULTIPLY AND CAUSE INFLAMMATION. OUR LONG-TERM GOAL IS TO DEVELOP SOLUTIONS FOR MAINTAINING UTERINE HEALTH THROUGH THE REGULATION OF BACTERIAL PRODUCTS. AIM 1 WILL DETERMINE IF THESE 3 BACTERIAL SPECIES INTERACT WITH EACH OTHER FOR ENHANCING GROWTH AND VIRULENCE. AIM 2 WILL IDENTIFY BACTERIAL PRODUCTS CREATED BY THE 3 BACTERIAL SPECIES DURING INFECTION OF HOST CELLS. AIM 3 WILL INVESTIGATE HOW BACTERIAL INTERACTIONS AND THEIR BACTERIAL PRODUCTS AFFECT HOST CELLS. OUR APPROACH FOR STUDYING INTERACTIONS OF ANAEROBIC BACTERIA WITH THE HOST USING A 3-D TISSUE CULTURE OF BOVINE ENDOMETRIUM WILL ILLUMINATE HOW THESE 3 BACTERIAL SPECIES INCREASE IN THE UTERUS AND CAUSE METRITIS IN DAIRY COWS. WE ANTICIPATE FINDING BACTERIAL PRODUCTS THAT AFFECT BACTERIAL PROLIFERATION AND HOST IMMUNE RESPONSE, WHICH CAN BE TRANSLATED INTO THERAPIES FOR PREVENTING AND TREATING METRITIS.$495,053

· FY2021 · National Institute of Food and Agriculture

OUR HYPOTHESIS IS THAT CHRONIC BOVINE RESPIRATORY DISEASE (BRD) IS A BACTERIAL BIOFILM DISEASE, WHICH MAKES THE BACTERIAL PATHOGENS ASSOCIATED WITH BRD MORE RESISTANT TO ANTIBIOTICS AND HOST IMMUNE DEFENSES. A BIOFILM IS AN ORGANIZED STRUCTURE OF BACTERIAL CELLS THAT ARE ENCASED IN A NETWORK OF POLYSACCHARIDE, NUCLEIC ACIDS, AND PROTEINS. THIS MATRIX MATERIAL CONTAINS WATER CHANNELS TO PROVIDE NUTRIENTS TO CELLS DEEP WITHIN THE BIOFILM, BUT THE CELLS THEMSELVES, THOUGH VIABLE, GROW VERY SLOWLY. AS A RESULT, BACTERIA WITHIN A BIOFILM ARE MORE RESISTANT TO ANTIBIOTICS AND HOST IMMUNE FACTORS DUE TO INACCESSIBILITY AND THE SLOW GROWTH OF THE BACTERIA (ANTIBIOTICS USUALLY ONLY KILL ACTIVLY GROWING CELLS). THE PRIMARY BACTERIAL PATHOGENS ASSOCIATED WITH BRD ARE HISTOPHILUS SOMNI, PASTEURELLA MULTOCIDA, MANNHEIMIA HAEMOLYTICA, AND MYCOPLASMA SPP., AND THEY MAY OCCUR ALONE, IN COMBINATION WITH EACH OTHER, OR WITH VIRAL AGENTS. THIS PROJECT FOCUSES ON THE RELATED BACTERIA H. SOMNI, P. MULTOCIDA, AND M. HAEMOLYTICA. THESE ORGANISMS RESIDE ONLY IN HOST MUCOSAL SITES, AND H. SOMNI AND M. HAEMOLYTICA RESIDE ONLY IN RUMINANTS (PRIMARILY BOVINES AND SHEEP). WE AND OTHERS HAVE ESTABLISHED THAT EACH OF THESE OPPORTUNISTIC PATHOGENS ARE CAPABLE OF FORMING BIOFILMS ON COVER SLIPS, TUBES, CULTURE PLATE WELLS, AND IN THEIR NATURAL HOST. WE HAVE ALSO SHOWN THAT H. SOMNI AND P. MULTOCIDA FORM A POLY-MICROBIAL BIOFILM TOGETHER IN LABORATORY VESSELS AND IN HOST TISSUES. HOWEVER, IT IS ESSENTIAL TO UNDERSTAND IF ALL 3 BACTERIA INTERACT TO FORM A BIOFILM TOGETHER, AND HOW SINGLE- AND POLY-MICROBIAL BIOFILMS DEVELOP AND BECOME ESTABLISHED IN THE HOST. ALTHOUGH CURRENT VACCINES DO INDUCE ANTIBODIES TO THESE BACTERIA, THAT ARE NOT ADEQUATELY EFFECTIVE AGAINST BRD. ANTIMICROBIALS ARE EXPENSIVE, AND EVEN IF EFFECTIVE, REQUIRE LONG PERIODS OF TREATMENT. WE PROPOSE THAT THE INEFFECTIVENESS OF CURRENT VACCINES AND ANTIMICROBIALS IS BECAUSE THE BACTERIA HAVE BECOME ESTABLISHED IN A BIOFILM, BUT THERE IS A LACK OF UNDERSTANDING OF HOW THESE BIOFILMS DEVELOP IN HOST TISSUES, AND HOW TO ELIMINATE OR REDUCE THE BIOFILM. THIS PROPOSAL AIMS TO FILL SOME OF THOSE GAPS IN KNOWLEDGE, AND IDENTIFY COMPOUNDS THAT MAY ENHANCE THE EFFICACY OF VACCINES AND ANTIMICROBIAL AGENTS.WE WILL FIRST DETERMINE IF ALL 3 OF THE BACTERIAL PATHOGENS MENTIONED ABOVE FORM A POLY-MICROBIAL BIOFILM TOGETHER (OUR FIRST AIM), AND THEN HOW THIS BIOFILM BECOMES ESTABLISHED AND DEVELOPS IN THE HOST THROUGH THE USE OF 3-D TISSUE CULTURE USING BOVINE RESPIRATORY EPITHELIAL CELLS (OUR SECOND AIM). THIS TYPE OF CELL CULTURE CAN MOST CLOSELY APPROXIMATE WHAT OCCURS IN THE BOVINE USING A MODEL THAT CAN BE OBSERVED ON AN HOURLY OR DAILY BASIS. WE WILL ALSO SCREEN AN EXTENSIVE LIBRARY OF THOUSANDS OF COMPOUNDS FOR THEIR CAPABILITY TO BREAK UP A SINGLE OR POLY-MICROBIAL BIOFILM, AND THOSE COMPOUNDSTHAT ARE DETERMINED TO BE SAFE FOR USE IN ANIMALS WILL BE FURTHER TESTED TO BREAK UP THE BIOFILM IN THE 3-D TISSUE CULTURE MODEL.,THEREAFTER, USING AN ANTIMICROBIAL BIOFILM DEVICE ASSAY, WE WILL DETERMINE IF THE BACTERIA WITHIN A BIOFILM ARE SIGNIFICANTLY MORE SUSCEPTIBLE TO A COMBINATION OF THE ANTIMICROBIAL AND THE ANTI-BIOFILM COMPOUND, THAN THE ANTIMICROBIAL ALONE (OUR THIRD AIM). IF SO, FURTHER DEVELOPMENT OF THESE COMPOUNDS WILL BE EXPLORED WITH PHARMACEUTICAL COMPANIES.IF SUCCESSFUL, THIS WORK WILL HAVE BENEFITS TO SOCIETY THATEXTEND MUCH FARTHER THAN ONLY TO IMPROVED TREATMENT OF BRD. BIOFILMS ARE COMMON IN MANY BACTERIAL DISEASES OF ANIMALS AND HUMANS, INCLUDING SWINE ATROPHIC RHINITIS, HUMAN CYSTIC FIBROSIS, ENDOCARDITIS, OSTEOMYELITIS, AND OTHERS. WE HOPE THAT THIS WORK WILL LEAD TO TREATMENT AND REMOVAL OF THE BIOFILM TO OBTAIN IMPROVED RESOLUTION OF CHRONIC BACTERIAL INFECTIONS.$485,000

· FY2019 · National Institute of Food and Agriculture

RUI: Improving Acoustic Estimates of Antarctic Krill Populations$440,000

· FY2004 · GEO

REU Site: The Intersection of Linguistics, Language, and Culture$398,471

· FY2017 · SBE

Collaborative ITR: Rigorous Techniques in Computational Problems with Distributed Adaptive Mesh Refinement$390,000

· FY2003 · MPS

HISTOPHILUS SOMNI CAUSES RESPIRATORY AND MANY OTHER DISEASES IN CATTLE. HOWEVER, THESE BACTERIA ALSO LIVE NORMALLY IN HOST MUCOSAL SITES, SUCH AS THE UPPER RESPIRATORY TRACT OR GENITAL TRACT, WITHOUT CAUSING DISEASE. H. SOMNI IS KNOWN AS AN OPPORTUNISTIC PATHOGEN, OR ONE THAT CAUSES DISEASE WHEN THE HOST IS STRESSED, WEAKENED, OR IS SUFFERING FROM ANOTHER INFECTION. BACTERIAL FACTORS THAT CONTRIBUTE TO DISEASE (VIRULENCE FACTORS) ENABLE H. SOMNI TO RESIST HOST DEFENSES, AND MOST OR ALL OF THESE FACTORS HAVE BEEN IDENTIFIED. FORMATION OF AN H. SOMNI BIOFILM, A LARGE COMMUNITY OF BACTERIA LIVING WITHIN A MATRIX OF MATERIAL COMPOSED OF POLYSACCHARIDES, DNA, AND PROTEINS, IS KNOWN TO OCCUR IN HOST TISSUES. THE GENES THAT ARE RESPONSIBLE FOR MAKING THESE VIRULENCE FACTORS HAVE ALSO BEEN IDENTIFIED. HOWEVER, IT IS NOW WELL ESTABLISHED THAT DIFFERENT FACTORS ARE PRODUCED ON THE BACTERIA DEPENDING ON WHERE IN THE HOST THE BACTERIA ARE RESIDING: THE LOWER RESPIRATORY TRACT, THE UPPER RESPIRATORY TRACT, THE BLOODSTREAM, JOINTS, ETC. SELECTIVE EXPRESSION OF DIFFERENT FACTORS AT DIFFERENT TIMES OR IN DIFFERENT HOST SITES INDICATES THAT EXPRESSION OF THE GENES FOR THESE VIRULENCE FACTORS IS HIGHLY REGULATED; IN OTHER WORDS THE EXPRESSION (MANUFACTURING) OF THESE FACTORS CA BE TURNED ON OR OFF. HOWEVER, NO WORK HAS BEEN REPORTED ON GENE REGULATION IN H. SOMNI. SMALL, NON-CODING (DO NOT PRODUCE A FUNCTIONAL PROTEIN) RNAS (SRNA) AND THE SRNA CHAPERONE HFQ (MUST BIN TO SRNA TO MAKE THEM FUNCTION) ARE GLOBAL REGULATORS; H. SOMNI HAS AT LEAST 94 SRNA AND HFQ. OUR HYPOTHESIS IS THAT SRNA AND HFQ REGULATE EXPRESSION OF MANY CRITICAL VIRULENCE FACTORS IN H. SOMNI. IDENTIFYING THESE SRNA, THE GENES THEY REGULATE, AND GENERATING MUTANT STRAINS LACKING OR OVER-EXPRESSING ONE OR MORE OF THESE FACTORS WILL ENABLE THE DESIGN OF IMPROVED VACCINES AND THERAPEUTICS. OUR AIMS ARE TO: 1) IDENTIFY H. SOMNI SRNA THAT BIND TO HFQ BY CAPTURING HFQ WITH ANTIBODIES TO HFQ AND DETERMINING WHICH SRNA ARE PRESENT BY SEQUENCING; 2) MUTATE HFQ IN A VIRULENT STRAIN OF H. SOMNI AND DETERMINE HOW THE VIRULENCE FACTORS HAVE CHANGED, AND IF THE MUTANT IS NO LONGER ABLE TO CAUSE DISEASE IN A BOVINE MODEL OF RESPIRATORY DISEASE; 3) OVER-EXPRESS SRNAS IN A VIRULENT H. SOMNI STRAIN TO DETERMINE WHETHER THIS MUTANT MAKES MORE OR LESS OF SEVERAL VIRULENCE FACTORS, INCLUDING BIOFILM, AND IF THEY CAN CAUSE MORE OR LESS DISEASE IN CATTLE. THIS PROJECT IS HIGHLY RELEVANT BECAUSE THE RESULTING INFORMATION AND/OR MUTANTS GENERATED MAY RESULT IN AN IMPROVED VACCINE OR THERAPEUTICS, WHICH CAN PREVENT PRODUCTION OF IMPORTANT VIRULENCE FACTORS RATHER THAN USE OF ANTIBIOTICS.$389,314

· FY2019 · National Institute of Food and Agriculture

ASTHMA EDUCATION, COUNSELING AND PREVENTION PROGRAM$348,798

H75 · FY2008 · EH

RUI: CAS: Novel Carbon Nanosphere Encapsulated Bimetallic Catalysts and Metal-CeO2 Interfaces for CO2 Conversion to Value-added Chemicals$316,588

· FY2023 · MPS

Collaborative Research: Well-Designed Nanofiber-Encapsulated Bimetallic Catalysts for CO2 Conversion: Addressing Catalyst Deactivation Challenges$314,880

· FY2025 · MPS

RUI: CAS: Carbon Dioxide Hydrogenation to Light Olefins over Carbon Nanosphere Encapsulated Metal/Metal Carbide Core-Shell Catalysts$300,000

· FY2020 · MPS

The Size-Distance Relation and the Moon Illusion$272,597

· FY2002 · SBE

WoU-MMA: Aspects of Compact Object Mergers$208,731

· FY2020 · MPS